Puerarin Reduces Radiation-Induced Vascular Endothelial Cell Damage Via miR-34a/Placental Growth Factor.
Chang LiuYing ZhaoXiaoting XuLei ZhangFeng-Mei CuiQiu ChenHongxia LiRu SangGen LiYong-Ming HePublished in: Dose-response : a publication of International Hormesis Society (2022)
The aim is to explore the protective effects of Puerarin on radiation-induced vascular endothelial cell damage and its underlying mechanism. The apoptosis and DNA damage of Human umbilical vascular endothelial cells (HUVECs) exposed to radiation alone or in combination with glucose in the exposed group were significantly elevated ( P < .05) compared with those in the control group. The Puerarin-treated HUVECs showed significant reduction in the radiation-induced apoptosis and DNA damage ( P < .05). Furthermore, X-ray irradiation significantly increased the expression of miR-34a, which was reversed by pre-treatment with Puerarin. Placental Growth Factor (PLGF) was a target gene of miR-34a. The expression of PLGF in the peripheral blood of patients receiving radiotherapy significantly increased with an increase in the cumulative dose of radiation ( P < .05), after which it began to decrease at the fourth week ( P < .05) and then remained at a low level until the end of radiotherapy. Puerarin exerts a radioprotective effect by decreasing DNA damage and apoptosis through miR-34a-targeted PLGF.
Keyphrases
- radiation induced
- growth factor
- oxidative stress
- dna damage
- endothelial cells
- induced apoptosis
- long non coding rna
- cell proliferation
- radiation therapy
- poor prognosis
- endoplasmic reticulum stress
- long noncoding rna
- dna repair
- peripheral blood
- cell death
- high glucose
- cell cycle arrest
- early stage
- magnetic resonance imaging
- squamous cell carcinoma
- locally advanced
- mass spectrometry
- clinical trial
- type diabetes
- binding protein
- vascular endothelial growth factor
- genome wide
- cancer therapy
- drug delivery
- computed tomography
- insulin resistance
- transcription factor